Chronic Myeloproliferative Disorders
What's New
Last Posted: Aug 02, 2018
- Local Coverage Determination (LCD): Flow Cytometry (L33661)
The U.S. Centers for Medicare & Medicaid Services - FAS/FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disorders.
Ozdemirkiran Fusun Gediz, et al. Archives of medical science : AMS 2017 3 (2) 426-432 - Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction.
Rai Praveer, et al. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 2016 9 - Low frequency of c-MPL gene mutations in Iranian patients with Philadelphia-negative myeloproliferative disorders.
Ghotaslou A, et al. Iranian journal of pediatric hematology and oncology 2015 0 (1) 43-9 - Matrix Metalloproteinases 2 and 9 Polymorphism in Patients With Myeloproliferative Diseases: A STROBE-Compliant Observational Study.
Maral Senem, et al. Medicine 2015 4 (16) e732 - Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
Karaköse Süleyman, et al. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2015 1 (1) 42-8 - Janus kinase (JAK) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorders.
De T, et al. Journal of the neurological sciences 2012 9 - Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.
Karkucak Mutlu, et al. Molecular biology reports 2012 9 (9) 8663-7 - A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders.
Hamidah N H, et al. La Clinica terapeutica 2012 0 (2) 109-13 - MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma Wanlong, et al. Diagnostic molecular pathology : the American journal of surgical pathology, part B 2011 3 (1) 34-9 - Chronic myeloproliferative disorders
From NCATS Genetic and Rare Diseases Information Center - Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.
Sazawal Sudha, et al. The Indian journal of medical research 2010 10 423-7 - JAK2 mutations in Asian patients with essential thrombocythaemia.
Wong G-C, et al. Internal medicine journal 2011 2 (2) 191-6 - Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders.
Stein Brady L, et al. Haematologica 2010 7 (7) 1090-7 - [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao Hong-Ying, et al. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2009 7 (7) 510-4 - Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.
Basquiera Ana L, et al. Hematology (Amsterdam, Netherlands) 2009 12 (6) 323-30 - Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation.
Er TK, et al. Clinica chimica acta; international journal of clinical chemistry 2009 7 - [The quantitative assay and clinical significance of JAK2V617F mutation in 131 patients with chronic myeloproliferative disorders].
Shen Yi-Min, et al. Zhonghua nei ke za zhi 2009 2 (2) 140-3 - HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative disease.
Andrikovics Hajnalka, et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009 3 (3) 929-34 - Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders.
Shen Y-M, et al. The Journal of international medical research 0 0 (1) 37-46
More
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:May 18, 2024
- Content source: